Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Mahdi, Gharaibeh"'
Autor:
Philip J. Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello, Mahdi Gharaibeh, David H. Collier
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-13 (2021)
Abstract Background Understanding the evolving treatment patterns in patients with rheumatoid arthritis (RA) is important for rheumatologists to make the best practice decisions and optimize treatment. Here, we describe treatment patterns among patie
Externí odkaz:
https://doaj.org/article/fd856b08f33c4bff829332d7fbb06ed2
Publikováno v:
BMC Medical Research Methodology, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background The importance of adjusting for cross-study heterogeneity in control group response rates when conducting network meta-analyses (NMA) was demonstrated using a case study involving a comparison of biologics for the treatment of mod
Externí odkaz:
https://doaj.org/article/e8c5cb4e56674c089b5539f128ad1b83
Autor:
Frederik Marmé, Aditya Bardia, Hope Rugo, Peter Schmid, Sara M. Tolaney, Mafalda Oliveira, Andreas Schneeweiss, Ling Shi, Wendy Verret, Mahdi Gharaibeh, Anju Shah, Javier Cortés
Publikováno v:
Cancer Research. 83:P4-07
Background: For HR+/HER2- metastatic breast cancer (MBC) patients, after resistance to endocrine therapy (ET), treatment options are mostly limited to traditional chemotherapies (CT) that offer poor survival and quality of life (QoL), creating an are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7563dfd85ab8b4c08925c914d359ac52
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-65
https://doi.org/10.1158/1538-7445.sabcs22-p4-07-65
Autor:
Sibylle Loibl, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O’Shaughnessy, Lisa A. Carey, Luca Gianni, Véronique Diéras, Ling Shi, Mahdi Gharaibeh, Luciana Preger, Lee Moore, See Phan, Martine Piccart
Publikováno v:
Cancer Research. 82:P5-16
Background: In ASCENT, patients with mTNBC refractory to or relapsing after ≥2 prior chemotherapies (at least one in the metastatic setting) were randomized 1:1 to receive sacituzumab govitecan (SG) or single-agent treatment of physician’s choice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42bd412c4d3acaa8d1d28340bec49ee4
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-01
https://doi.org/10.1158/1538-7445.sabcs21-p5-16-01
Autor:
Sibylle Loibl, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam M. Brufsky, Kevin Kalinsky, Javier Cortés, Joyce A. O'Shaughnessy, Véronique Dieras, Lisa A. Carey, Luca Gianni, Mahdi Gharaibeh, Luciana Preger, See Phan, Lawrence Chang, Ling Shi, Martine J. Piccart
Publikováno v:
Scientia
Quality of life; Sacituzumab govitecan; Triple-negative breast neoplasms Qualitat de vida; Sacituzumab govitecan; Neoplàsies de mama triple negatiu Calidad de vida; Sacituzumab govitecan; Neoplasias de mama triple negativo Background The antibody–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d5f54a313c3f41b473e8f27fd0b5f3
https://pubmed.ncbi.nlm.nih.gov/36379186
https://pubmed.ncbi.nlm.nih.gov/36379186
Autor:
Ervant J Maksabedian Hernandez, Mahdi Gharaibeh, Donna McMorrow, Machaon Bonafede, Bradley S. Stolshek
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 26:1039-1049
Targeted immunomodulators (TIMs) are used for the treatment of moderate to severe rheumatoid arthritis (RA) and include biologic and nonbiologic medications with different mechanisms of action. Data describing disease activity levels in RA are not di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72af61a590e43fef776814d34cf48c0c
https://doi.org/10.18553/jmcp.2020.26.8.1039
https://doi.org/10.18553/jmcp.2020.26.8.1039
Autor:
Nancy K. Sweitzer, Mahdi Gharaibeh, Marion K. Slack, Brian L. Erstad, Christopher S. Lee, Ivo Abraham, Jason H. Karnes, Walter T. Klimecki, Nimer S. Alkhatib, Kenneth S. Ramos
Publikováno v:
American Journal of Cardiovascular Drugs. 21:205-217
Objective The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d622b6beeeacd2fb67f49ee23bb36085
https://doi.org/10.1007/s40256-020-00425-x
https://doi.org/10.1007/s40256-020-00425-x
Autor:
Neil A. Accortt, Carol J. Etzel, Girish A. Aras, Philip J. Mease, Sabrina Rebello, Ryan W. Harrison, David H. Collier, Jeff Greenberg, Mahdi Gharaibeh
Publikováno v:
Rheumatology International. 39:1547-1558
This study described treatment patterns in a psoriatic arthritis (PsA) patient registry for new or ongoing tumor necrosis factor inhibitor (TNFi) monotherapy, conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy, or TNFi/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83baba96828844bacfe9fd3d1605acf4
https://doi.org/10.1007/s00296-019-04345-1
https://doi.org/10.1007/s00296-019-04345-1
Autor:
Lawrence Chang, Peter S. Hall, Luciana Preger, Nikoleta Sjekloca, Estevan Bergamaco, Anne Broe, Plamena Petrova, Paul Berg, Adam Reich, Neha Pawar, Mahdi Gharaibeh
Publikováno v:
Journal of Clinical Oncology. 40:1075-1075
1075 Background: TNBC is the most aggressive type of breast cancer due to rapid growth, metastasis, and recurrence post-treatment. This study aimed to assess real-world treatment patterns and survival of pts with mTNBC who received 2L and 3L therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d11bbc86e701cff42198289a619f14e
https://doi.org/10.1200/jco.2022.40.16_suppl.1075
https://doi.org/10.1200/jco.2022.40.16_suppl.1075
Autor:
Ervant J Maksabedian Hernandez, David H. Collier, Joseph Tkacz, Jeroen P. Jansen, L. Moore-Schiltz, Devin Incerti, Mahdi Gharaibeh, Bradley S. Stolshek
Publikováno v:
Journal of managed carespecialty pharmacy. 26(10)
Patients with moderate to severe rheumatoid arthritis (RA) occasionally increase their doses of tumor necrosis factor (TNF) inhibitors, especially the monoclonal antibody origin drugs such as adalimumab and infliximab, after inadequate response to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0da9d58b7f0a85b507153c449cf6b4c
https://pubmed.ncbi.nlm.nih.gov/32996384
https://pubmed.ncbi.nlm.nih.gov/32996384